BioSpace News Archive

The 7,300 square foot facility features a clean-room manufacturing environment and environmentally controlled test labs

F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today that it will host a full year 2020 investor conference call and webcast on Monday, March 29, 2021 at 9:00 a.m. EDT.

Amolyt Pharma, a global company specializing in developing therapeutic peptides for rare endocrine and metabolic diseases, today announced that it will be presenting four abstracts at the Endocrine Society’s Annual Meeting, ENDO 2021, being held virtually from March 20-23, 2021.

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that The Journal of Emergency Medicine has published results from a post-hoc analysis of clinical data from the pivotal Lefamulin Evaluation Against Pneumonia (LEAP) 2 Phase 3 clinical trial.

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report fourth quarter and full year 2020 financial results and provide a corporate update after the market close on Tuesday, March 23, 2021.

Study to evaluate pharmacokinetics, safety and tolerability of VTX-958 as well as effects on biomarkers of TYK2-driven inflammatory signaling

Lyell Immunopharma, Inc., an immuno-oncology company dedicated to the mastery of T cells to cure solid tumors, announced the appointment of Richard Sherry, M.D., as Senior Vice President, TIL Specialist and Clinical Lead.

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced publication of the pivotal manuscript from the AMPREVENCE clinical trial in the highly respected American Journal of Obstetrics and Gynecology (AJOG). This double-blinded, placebo-controlled, multicenter study of EVO100 met its primary and secondary efficacy endpoints

Vesigen Therapeutics, Inc., a biotechnology company pioneering a novel extracellular vesicle delivery technology to develop transformative therapeutics, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 10,945,954 entitled “ARRDC1-Mediated Microvesicles (ARMMs) and Uses Thereof”.

will augment the company’s thermal packaging solutions with Cloudleaf’s Digital Visibility Platform to prevent spoilage and improve delivery efforts for critical drugs and biologics, including the vaccines deployed to battle the COVID-19 pandemic